Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION: Recent research has indicated serotonergic and dopaminergic abnormalities in the superior temporal gyrus of patients with a history of chronic auditory hallucinations. Both loxapine and aripiprazole have effects on dopaminergic and postsynaptic serotonergic (5-HT₂A) receptor systems, which could account for synergistic effects in treating refractory hallucinations. The combination appears safe, even when loxapine is given in high dosages. Patients should be monitored for the development of parkinsonian tremors. CONCLUSIONS:
|
Authors | Kenneth N Sokolski |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 45
Issue 7-8
Pg. e36
(Jul 2011)
ISSN: 1542-6270 [Electronic] United States |
PMID | 21672885
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Serotonin 5-HT2 Receptor Antagonists
- Aripiprazole
- Loxapine
|
Topics |
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects, therapeutic use)
- Aripiprazole
- Dose-Response Relationship, Drug
- Drug Monitoring
- Drug Resistance
- Drug Therapy, Combination
(adverse effects)
- Hallucinations
(etiology, prevention & control)
- Humans
- Loxapine
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Piperazines
(administration & dosage, adverse effects, therapeutic use)
- Quinolones
(administration & dosage, adverse effects, therapeutic use)
- Schizophrenia
(drug therapy)
- Serotonin 5-HT2 Receptor Antagonists
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|